首页> 美国卫生研究院文献>other >Soluble HMGB1 Is a Novel Adipokine Stimulating IL-6 Secretion through RAGE Receptor in SW872 Preadipocyte Cell Line: Contribution to Chronic Inflammation in Fat Tissue
【2h】

Soluble HMGB1 Is a Novel Adipokine Stimulating IL-6 Secretion through RAGE Receptor in SW872 Preadipocyte Cell Line: Contribution to Chronic Inflammation in Fat Tissue

机译:可溶性HMGB1是一种新型的脂肪因子可通过SW872前脂肪细胞系中的RAGE受体刺激IL-6分泌:对脂肪组织中慢性炎症的贡献。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Low-grade inflammation (LGI) is a central phenomenon in the genesis of obesity and insulin-resistance characterized by IL-6 in human serum. Whereas this LGI was initially thought to be mainly attributed to macrophage activation, it is now known that pre-adipocytes and adipocytes secrete several adipokines including IL-6 and participate to LGI and associated pathologies. In macrophages, HMGB1 is a nuclear yet secreted protein and acts as a cytokine to drive the production of inflammatory molecules through RAGE and TLR2/4. In this paper we tested the secretion of HMGB1 and the auto- and paracrine contribution to fat inflammation using the human preadipocyte cell line SW872 as a model. We showed that 1) human SW872 secreted actively HMGB1, 2) IL-6 production was positively linked to high levels of secreted HMGB1, 3) recombinant HMGB1 boosted IL-6 expression and this effect was mediated by the receptor RAGE and did not involve TLR2 or TLR4. These results suggest that HMGB1 is a major adipokine contributing to LGI implementation and maintenance, and can be considered as a target to develop news therapeutics in LGI associated pathologies such as obesity and type II diabetes.
机译:低度炎症(LGI)是肥胖和胰岛素抵抗的起源中的主要现象,其特征是人血清中的IL-6。最初认为该LGI主要归因于巨噬细胞活化,但现在已知前脂肪细胞和脂肪细胞分泌几种脂肪因子,包括IL-6,并参与LGI和相关病理。在巨噬细胞中,HMGB1是一种核内但尚未分泌的蛋白质,并作为细胞因子来驱动通过RAGE和TLR2 / 4产生炎症分子。在本文中,我们以人脂肪细胞前细胞系SW872为模型,测试了HMGB1的分泌以及自分泌和旁分泌对脂肪炎症的贡献。我们显示了1)人类SW872主动分泌HMGB1,2)IL-6的产生与高水平分泌的HMGB1正相关,3)重组HMGB1增强了IL-6的表达,这种作用是由受体RAGE介导的,并不涉及TLR2或TLR4。这些结果表明,HMGB1是有助于LGI实施和维持的主要脂肪因子,可以被认为是开发与肥胖症和II型糖尿病等LGI相关疾病的新闻疗法的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号